阿托伐他汀下调肿瘤坏死因子-α诱导的人脐静脉内皮细胞NF-κB的表达
被引量:2
摘要
阿托伐他汀(atorvastation,AT)作为一种有效的他汀类降血脂药,能够降低血清胆固醇和低密度脂蛋白,近年发现AT在病理生理学方面还具有抗炎、抗氧化及稳定动脉硬化斑块的作用,然而AT稳定动脉硬化斑块的确切机制至今尚未明了。NF-κB是一种重要的炎症、凋亡因子,作为多种炎症、细胞因子的中间环节,参与正负反馈调节机制,本实验拟研究AT稳定动脉硬化斑块与NF-κB表达、分泌之间的内在联系,探讨AT稳定动脉硬化斑块的作用机制,现报道如下。
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2013年第10期1061-1063,共3页
Chinese Journal of Cellular and Molecular Immunology
参考文献12
-
1Fuseler JW, Merrill DM, Rogers JA, et al. Analysis and quantitation of NF-kappaB nuclear translocation in tumor necrosis factor alpha (TNFa) activated vascular endothelial cells [ J ]. Microsc Microanal, 2006, 12 (3) : 269 -276.
-
2毛德军,高丽丽,郭瑞友,侯荣耀.沙土鼠脑缺血后海马CA1区神经细胞凋亡、相关基因表达及亚低温的干预作用[J].中华神经医学杂志,2008,7(11):1090-1093. 被引量:2
-
3Dahlman JM, Bakkar N, He W, et al. NF-KB functions in stromal fibroblasts to regulate early potnatal muscle development[ J]. J Biol Chem, 2010, 285(8): 5479-5487.
-
4Yang J, Huang C, Yang J, et al. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: a key role for TLR4/NF-kappaB signaling pathway[J]. Mol Cell Biochem, 2010, 345(4) : 189 -195.
-
5Zerfaoui M, Suzuki Y, Naura AS, et al. Nuclear translocation of p65 NF-KB is sufficient for V CAM-l, but not ICAM-1, expression in TNF- stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction[J]. Cell Signal, 2008, 20( 1 ) : 186 - 194.
-
6Murrell M, Khachigian LM, Ward MR. Divergent roles of NF-KB and Egr-1 in ow-dependent restenosis after angioplasty and stenting [ J]. Atherosclerosis, 2011, 214 ( 1 ) : 65 -72.
-
7Grassia G, Maddaluno M, Musini C, et al. The IKB kinase inhibitor nuclear factor- KB essential modulatorbinding domain peptide for inhibition of injury-induced neointimal formation [ J ]. Arterioscler Thromb Vase Bid, 2010, 30(12): 2458-2466.
-
8严丽洁,王丽霞,段红艳,王山岭,李永强,杨海涛.阿托伐他汀对亚临床动脉粥样硬化患者颈动脉内-中膜厚度的影响[J].中华实用诊断与治疗杂志,2012,26(2):180-182. 被引量:18
-
9周锐.阿托伐他汀钙治疗颈动脉粥样硬化疗效观察[J].中国实用神经疾病杂志,2010,13(2):9-11. 被引量:50
-
10Zhou Q, Liao JK. Pleiotropic effects of statins-basic research and clinic perspectives[J]. Circ J, 2010, 74(5) : 818 -826.
二级参考文献50
-
1毛德军,唐咏春,李菲,高丽丽.亚低温对大鼠脑缺血-再灌注后神经胶质细胞分泌神经生长因子的影响[J].中国危重病急救医学,2005,17(3):187-187. 被引量:3
-
2刘亚平,张莹,王从旭,李博.脑梗死与颈动脉粥样斑块的相关性分析[J].中国脑血管病杂志,2005,2(4):153-155. 被引量:72
-
3谢坚,章成国.他汀类药物预防缺血性脑卒中的评价[J].临床神经病学杂志,2005,18(6):471-472. 被引量:30
-
4刘俊艳,沈宏锐.阿托伐他汀抗动脉粥样硬化的分子机制研究[J].脑与神经疾病杂志,2006,14(2):99-101. 被引量:41
-
5刘恒方,杨期东,李新华,苗旺.颈动脉粥样硬化斑块ABCA1表达及辛伐他丁干预的影响[J].中风与神经疾病杂志,2007,24(2):199-201. 被引量:16
-
6Charriant-Marlangue, IM Argaill, Represa A, et al. Apoptosis and neurosis after reversible focal ischemia: an in situ DNA-fragmentation analysis [J]. J Cereb Blood Flow Metab, 1996,16(2): 184-194.
-
7Colboume, Corbett D. Delayed and prolonged post-ischemic hypothermia is neuroprotective in the gerbil[J]. Brain Res, 1994, 654(2): 265-272.
-
8Berti R, Williams AJ, Moffett JR, et al. Quantitative real-time RT-PCR analysis of inflammatory gene express associated with ischemia-reperfusion brain injury [J]. J Cere Blood Flow Metab, 2002, 22(9): 1068-1079.
-
9Liu SJ, Zhou SW, Xue CS. Effect of tetrandrine on neutrophilic recruitment response to brain ischemia/ reperfusion [J]. Acta Pharmacol Sin, 2001,22(11): 971-975.
-
10Li J J, Fang CH. Creative protein is not only an inflammatory maker but also a direct cause of cardiovascular disease[J]. Med Hypotheses, 2003,62 : 49.
共引文献76
-
1孔娟,陈燕.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效观察[J].医学信息(医学与计算机应用),2014,0(26):590-590.
-
2庞振阳.颈动脉粥样硬化斑块的发生与他汀药物治疗的进展综述[J].医学信息(医学与计算机应用),2014,0(9):581-581. 被引量:1
-
3毛德军,唐咏春,郭瑞友,战淑彩,臧云华.核因子-κB1-94ins/delATTG基因多态性与中国青岛地区汉族人群急性进展性脑梗死相关性的研究[J].中华神经医学杂志,2010,9(5):487-491. 被引量:3
-
4何玉清.阿托伐他汀钙治疗颈动脉粥样硬化86例疗效观察[J].中国实用医药,2010,5(33):162-163. 被引量:8
-
5杨倩红,陆洁,程小文,冯琳,顾海蔚,吴积炯,苏静英.阿托伐他汀与辛伐他汀对老年颈动脉粥样硬化干预的对比分析[J].中华老年心脑血管病杂志,2011,13(2):151-153. 被引量:10
-
6周静.氟伐他汀联合阿司匹林治疗颈动脉粥样硬化斑块的临床观察[J].中国现代医生,2011,49(11):43-43. 被引量:2
-
7成晓,叶建新,林航,穆军山.他汀类药物对缺血性卒中患者神经保护机制的研究进展[J].中国脑血管病杂志,2011,8(7):388-392. 被引量:7
-
8徐园园,马亮,魏迎风,翟林云.瑞舒伐他汀辅治糖尿病合并颈动脉粥样硬化的临床观察[J].临床合理用药杂志,2011,4(21):66-67. 被引量:4
-
9李进,王革,徐琦.阿托伐他汀钙对颈动脉粥样硬化的疗效观察[J].中国现代医生,2012,50(5):70-70. 被引量:8
-
10朱华伟,邓建中,齐进兴.阿托伐他汀钙治疗颈动脉粥样硬化临床疗效观察[J].中国实用医药,2012,7(1):191-192. 被引量:2
同被引文献27
-
1Sanchez AP, Sharma K. Transcription factors in the pathogenesis of di- abetic nephropathy[ J]. Expert Rev Mol Med, 2009,11 :e13.
-
2Gensini GF, Coil AM, Dilaghi B. Effect of atorvastatin on circulating hs-CRP concentrations: A sub-study of the Achieve Cholesterol Tar- gets Fast with Atorvastatin Stratified (ACTFAST) sdudy [ J ]. Int J Cardio1,2010,142 ( 3 ) : 257 - 264.
-
3DeFuria J1, Belkina AC, Jagannathan-Bogdan M, et al. B cells pro- mote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile [ J ]. Pine Natl Acad Sci U S A,2013,110(13) :5133 -5138.
-
4Melloul D. Role of NF kappaB in beta-cell death [ J ]. Biochem Soc Trans ,2008,36 ( 3 ) :334 - 339.
-
5Yeo ES, Hwang JY, Park JE, et, al. Tumor necrosis faetor(TNF-al- pha) and C-reactive protein(CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes [ J ]. Yonsei Med J,2010,51 (4) :519-525.
-
6Ignillo-Esteve M, Marselli L, Cunha DA, et,al. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta ceils in type 2 diabetes [ J]. Diabetologia, 2010,53 (7) : 1395 - 1405.
-
7Lougbrey BV, McGinty A, Young IS, et, al. Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low- dose atorvastatin treatment : evidence from a randomized controlled tri- al[J]. Clinical Endocrinology,2013,79(6) :800 -806.
-
8Raddino R, Della Pina P, Gavazzoni M, et al. Effect of high dose of at orvastatin versus moderate dose on endothelial function and inflam- matory biomarkers in patients with STEMI [ J ]. American College Cardiology,2013, 61(10 suppl. 1 ) :218.
-
9Hernandez C, Francisco G, Ciudin A, et al. Effect of atorvastatin on lipoprotein(a) and interleukin-10: a randomized placebo-controlled trial[J]. Diabetes Metab,2011,37(2) :124-130.
-
10李建英,路文盛,刘斐,郭进,陈健,叶伟林.阿托伐他汀对早期糖尿病肾病老年患者外周血NF-κB和尿白蛋白排泄率的影响[J].实用医学杂志,2011,27(11):1956-1958. 被引量:12
二级引证文献4
-
1刘英,周英,杨海燕,张海娜,王志娥.不同剂量阿托伐他汀对老年早期糖尿病肾病患者NF-κB、炎性因子及胰岛素抵抗的影响研究[J].海南医学院学报,2016,22(1):45-47. 被引量:22
-
2李建英.老年早期糖尿病肾病患者尿白蛋白排泄率相关因素分析[J].中国临床新医学,2015,8(12):1120-1123.
-
3张荣,靳建忠.血清IL-6TNF-α及hs-CRP联合监测对早期糖尿病肾病的诊断价值分析[J].基层医学论坛,2015,19(35):4948-4949.
-
4刘勇,刘艳丽,莫松柳,张利锋,李满洪,黄佳娜,赵洪磊.不同剂量阿托伐他汀治疗非ST段抬高型急性冠脉综合征效果比较[J].中国临床新医学,2019,12(10):1071-1074. 被引量:4
-
1张启祥.他汀类降血脂药的非降脂作用评价[J].中国现代应用药学,2006,23(S2):747-750. 被引量:3
-
2何纯生.2012~2014年我院他汀类降血脂药使用情况分析[J].中国现代药物应用,2015,9(16):138-140. 被引量:1
-
3赖敏.低分子肝素钙小剂量尿激酶治疗不稳定性心绞痛临床分析[J].医学文选,2003,22(6):863-864.
-
4杨世亭.他汀类药物与其他药物的相互作用[J].中国医刊,2012,47(11):3-5. 被引量:5
-
5匡丽萍,兰海霞.我院2004-2007年降血脂药物应用分析[J].西北药学杂志,2009,24(2):152-152. 被引量:8
-
6丁既鹏.辛伐他汀调血脂作用和不良反应的临床研究[J].临床荟萃,2004,19(12):703-704. 被引量:8
-
7涂洁琼,杨孟明,李存仁.调血脂药用药情况分析[J].西北药学杂志,2015,30(3):305-307. 被引量:3
-
8赵维,张弦.2010—2012年解放军305医院他汀类降血脂药使用分析[J].中国医院用药评价与分析,2014,14(4):351-353. 被引量:7
-
9李雪峰,杨骄霞,冯浩.树突状细胞与动脉粥样硬化[J].牡丹江医学院学报,2008,29(2):70-73.
-
10康博士.他汀类降血脂药还能用吗[J].健康指南(中老年),2012(11):67-67.